Alterity Therapeutics Limited (ATHE)
ATHE Stock Price Chart
Explore Alterity Therapeutics Limited interactive price chart. Choose custom timeframes to analyze ATHE price movements and trends.
ATHE Company Profile
Discover essential business fundamentals and corporate details for Alterity Therapeutics Limited (ATHE) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
29 Sept 2003
Employees
10.00
Website
https://alteritytherapeutics.comCEO
David A. Stamler
Description
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
ATHE Financial Timeline
Browse a chronological timeline of Alterity Therapeutics Limited corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 4 Aug 2025
Earnings released on 28 Feb 2025
EPS came in at -$0.00 surpassing the estimated -$0.53 by +99.87%, while revenue for the quarter reached $802.96K , missing expectations by -65.14%.
Earnings released on 3 Feb 2025
EPS came in at -$0.00 , while revenue for the quarter reached $802.96K .
Earnings released on 29 Aug 2024
EPS came in at -$0.00 surpassing the estimated -$0.05 by +96.21%, while revenue for the quarter reached $2.12M , beating expectations by +123.01%.
Earnings released on 11 Apr 2024
EPS came in at -$0.00 , while revenue for the quarter reached $1.06M .
Earnings released on 28 Feb 2024
EPS came in at -$0.00 surpassing the estimated -$0.11 by +97.53%, while revenue for the quarter reached $1.90M , beating expectations by +98.35%.
Earnings released on 30 Jan 2024
EPS came in at -$0.00 , while revenue for the quarter reached $950.36K .
Earnings released on 30 Jun 2023
EPS came in at -$0.00 , while revenue for the quarter reached $1.53M .
Earnings released on 31 Mar 2023
EPS came in at -$0.00 surpassing the estimated -$0.12 by +99.01%, while revenue for the quarter reached $765.25K , missing expectations by -48.96%.
Earnings released on 28 Feb 2023
EPS came in at -$1.11 surpassing the estimated -$1.81 by +38.62%, while revenue for the quarter reached $7.67K , missing expectations by -99.58%.
Stock split effective on 9 Jan 2023
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 31 Dec 2022
EPS came in at -$0.00 , while revenue for the quarter reached $2.39M .
Earnings released on 30 Aug 2022
EPS came in at -$1.43 surpassing the estimated -$1.97 by +27.48%, while revenue for the quarter reached $1.82M , missing expectations by -36.46%.
Earnings released on 30 Jun 2022
EPS came in at -$0.00 , while revenue for the quarter reached $2.76M .
Earnings released on 28 Feb 2022
EPS came in at -$0.98 , while revenue for the quarter reached $980.00 .
Earnings released on 31 Dec 2021
EPS came in at -$0.00 , while revenue for the quarter reached $2.36M .
Earnings released on 31 Aug 2021
Earnings released on 30 Jun 2021
EPS came in at -$0.00 , while revenue for the quarter reached $2.46M .
Earnings released on 25 Feb 2021
Earnings released on 31 Dec 2020
EPS came in at -$0.01 , while revenue for the quarter reached $1.88M .
ATHE Stock Performance
Access detailed ATHE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.